Shionogi & Co., Ltd. is a research-driven global pharmaceutical company headquartered in Osaka, Japan. Established in 1878, Shionogi specializes in the discovery, development, manufacturing and marketing of prescription medicines across a broad spectrum of therapeutic areas. The company’s core business activities encompass anti-infectives, central nervous system (CNS) therapies, pain management, cardiovascular treatments and oncology drugs. Through its unsponsored American depositary receipt program, Shionogi’s ordinary shares trade over the counter in the U.S. under the ticker SGIOY.
Shionogi maintains a robust pipeline focused on addressing unmet medical needs, particularly in infectious diseases and antibiotic resistance. Its commercial portfolio includes Xofluza (baloxavir marboxil) for the treatment of influenza, as well as a range of antibiotics and antivirals. The company also markets CNS agents for neuropathic pain and sleep disorders, and has expanded into oncology with targeted therapies currently in clinical development. Strategic partnerships with global pharmaceutical firms support Shionogi’s research efforts and facilitate the co‐development and licensing of novel compounds.
Operating across Asia, North America, Europe and other regions, Shionogi leverages a network of subsidiaries and joint ventures to commercialize its products internationally. In the United States and Europe, the company has established clinical development hubs and manufacturing alliances to support local regulatory submissions and to ensure supply chain resilience. In emerging markets throughout Asia and Latin America, Shionogi collaborates with regional partners to improve patient access to its therapies and to strengthen healthcare infrastructure.
Over its more than 140‐year history, Shionogi has evolved from a domestic pharmaceutical wholesaler into a global innovator in drug discovery and development. The company is led by President and CEO Yoshihiro Kamoshita, under whose direction Shionogi has prioritized sustainable growth, corporate citizenship and patient‐centric innovation. With a commitment to improving quality of life through science, Shionogi continues to expand its pipeline, pursue strategic collaborations and explore next‐generation technologies such as antimicrobial peptides and biologics.
